Greater access to IPOs through OnMarket BookBuilds

amscot has partnered with OnMarket BookBuilds to provide our clients with even more investment opportunities. In addition to the exclusive capital raisings that amscot undertakes and offers to our clients, you can now take advantage of offers from OnMarket. Our association with OnMarket will allow you to bid directly on IPOs and have the shares allocated straight to your holdings at amscot. Through OnMarket our clients will also be able to access free research, management interviews and get notifications on upcoming IPOs.

OnMarket is Australia’s first online platform that lets all investors buy shares in IPOs free of any fees other than the cost of the shares. Since launching in October 2015 OnMarket has hosted 1 in 3 ASX IPOs, so we are obviously excited to be able to offer our clients access to this cutting-edge platform. For each offer hosted by OnMarket you get easy bidding & payment, free independent research, and a chance to 'meet the management' via exclusive video interviews. Best of all, when you invest in IPOs via OnMarket, any shares you buy can be allocated directly to your amscot Stockbroking account so you can manage your portfolio without disruption.

How does it work?

We will display the list of current offers from OnMarket on our website. If you see an offer that you want to invest in then click on the Bid Now button to apply for shares. You will leave amscot website and be redirected to our partner's (OnMarket) bidding platform where you will need to sign up with your Holder Identification Number (HIN). If you have already signed up then you will be taken straight to the bidding page for the selected offer.

It is important that you enter your HIN correctly when you set up your login at OnMarket. This will make for a seamless experience if you want your shares to be automatically allocated to your amscot account.

Current OnMarket Offers

IPO
Biotech
$0.20
Size of Offer $4-6 million
Minimum Bid $2,000.00
Opening Date 8/06/2017
Closing Date 16/07/2017

Sienna Cancer Diagnostics Limited (ASX: SDX) is an Australian company that has developed, and commercialised, a new technology with application in the early detection of cancer.

Sienna has launched an in vitro diagnostic (“IVD”) test to detect human TElomerase Reverse Transcriptase (“hTERT”), recognized as an important cancer-related biomarker. The first application of the test is as an adjunct to urine cytology to assist in the diagnosis of bladder cancer. 

Regulatory approvals

Sienna has registered its IVD test for human clinical use with the relevant authorities in the USA, Europe  and Australia. The technology is currently in routine use in commercial laboratories in the USA, generating revenues of $292k for the six months to December 2017.

Distribution channels

Supply and distribution agreements have been executed with partners in the USA, the UK and Switzerland, with additional partnerships being developed in a number of other countries. StatLab, a pathology supply company that has significant presence in the US market, has been appointed as the distribution partner for the USA.

Market opportunity

Sienna will be targeting a market segment of urine cytology, including bladder cancer detection. In the USA alone this market opportunity is estimated to be between 1.3 and 1.6 million tests per annum.  Sienna’s test is eligible for an average reimbursement of US$108.38 per test in the USA creating a total market value for laboratories in the USA of over US$140 million per year.  The rest of world outside the USA represents a significant additional market opportunity.

Future growth

The company believes future revenue growth may be achieved through:

  • increased market penetration in the USA.
  • geographical expansion into additional countries across Europe, Asia and the rest of the world.
  • expanding the clinical applications of the product into additional cancer types.
  • adding new biomarker products to the pipeline through in-license or acquisition.

Historical revenues

Sienna received first product revenues during the 2015 FY. Total revenue for the half-year to 31 December 2016 was $935,793, including $291,588 of product revenue and $637,523 received from the Australian Government’s R&D Tax Incentive program.

Offer overview

Sienna is looking to raise between $4 million and $6 million via its IPO and on listing, the expected market capitalisation at IPO will be $35.5 million to $37.5 million.

 

As set out in Section 14 of the Prospectus, Sienna Cancer Diagnostics Limited is subject to a range of risks, including but not limited to commercialisation and intellectual property risks, sufficiency of funding and the expenditure program.

 

Section 734(6) disclosure: The issuer of the securities is Sienna Cancer Diagnostics Limited ACN 099 803 460. The securities to be issued are ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. Anyone who wants to acquire the securities will need to complete the application form that will be in or will accompany the disclosure document (which can be done via the electronic application form which will become available by clicking the bid button above).​

Disclaimer: All information on this section is of a general nature. Before making any investment decision, please seek the relevant advice.

Back to top